
PHARMACEUTICAL 2022

Aravive Inc. Rank 336 of 475







PHARMACEUTICAL 2022

Aravive Inc. Rank 336 of 475



The relative strengths and weaknesses of Aravive Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aravive Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 38% points. The greatest weakness of Aravive Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 160% points.

The company's Economic Capital Ratio, given in the ranking table, is -241%, being 35% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	62,745
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,941
Liabilities, Non-Current	7,624
Other Assets	4,642
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,498
Property and Equipment	400
Research and Development	37,541
Revenues	7,442
Selling, General and Administrative Expense	10,550

Output Variable	Value in 1000 USD
Assets	67,787
Liabilities	25,565
Expenses	48,091
Stockholders Equity	42,222
Net Income	-39,151
Comprehensive Net Income	-39,151
Economic Capital Ratio	-241%